中国人群CYP1A1基因Exon7多态性及吸烟与肺癌易感性的关系

Relationship of CYP1A1 Exon7 polymorphism and smoking on susceptibility of lung cancer in Chinese people

目的探讨中国人群CYP1A1基因Exon7位点多态性及吸烟与肺癌易感性的关系。方法制订纳入标准和排除标准,计算机检索中国期刊网全文数据库(CKNI)、万方数据库、维普数据库、Pubmed数据库建库至2014年1月的相关文献,并结合文献追溯等方法,收集关于中国人群CYP1A1基因Exon7位点多态性与肺癌的关系且有吸烟分型的病例-对照研究。统计对应的吸烟组及非吸烟组的研究数据,采用Stata10.0软件对各研究原始结果进行统计处理,计算合并OR值及95%置信区间(95%CI)。结果共纳入7篇中文、1篇英文文献,均为病例-对照研究。吸烟组中,突变型基因(Val/Val+Ile/Val)与野生型基因(Ile/Ile)比较,其合并OR值为1.759,95%CI(1.389,2.226);而该位点在非吸烟组中的合并OR值为1.256,95%CI(0.946,1.668)。结论 CYP1A1基因Exon7位点多态性可能与肺癌易感性有关,且CYP1A1基因Exon7位点多态性与吸烟在肺癌的发生中有协同作用。

Objective To explore the relationship between CYP1A1Exon7 polymorphism with the susceptibility of lung cancer in Chinese people.Methods The inclusion and exclusion criteria were formulated.The related literatures were retrieved in the China National Knowledge Infrastructure（CNKI）,Wanfang,Weipu and Pubmed databases from their establishment to January 2014.The case-control studies on the relationship between CYP1A1Exon7 polymorphism with lung cancer and on the smoking classification were collected by combining with the methods of literature tracing back,etc.The corresponding research data in the smoking group and the non-smoking group were statisticlly analysed,and the original results of each study were conducted the statistical analysis for calculating the merged odds ratio（OR）and 95% confidence interval（CI）by using the Stata10.0software.Results 7Chinese articles and 1English article were included and all of them were case-control studies.In the smoking group,the joint risk for those carrying mutant genotypes（Val/Val and Ile/Val）was significantly higher than that for those carrying Ile/Ile genotypes[OR=1.759,95%CI（1.389,2.226）,P〈0.05];in the non-smoking group,the joint risk for those carrying mutant genotypes was 1.256 times higher[OR=1.256,95%CI（0.946,1.668）,P〉0.05].Conclusion The CYP1A1Exon7 polymorphism may be related to the susceptibility of lung cancer,and may have the synergic reaction with smoking in the occurrence of lung cancer.